LAS VEGAS, January, 2017 – ROM Plus® and AmniSure® faced off in a highly anticipated prospective observational head to head study that was presented during the 2017 SMFM Pregnancy Meeting at Caesar’s Palace. The study consisted of 111 patients, where test results were compared to clinical confirmation via a comprehensive clinical chart review. The overall sensitivity of ROM Plus and AmniSure were, 96.4% and 89.3% respectively. The reported specificity of each test was ROM Plus 98.8% and AmniSure 100%.
ROM Plus Poster & Abstract from SMFM 2017 Pregnancy Meeting
Parker Holt 2017-05-11T17:25:12+00:00